Eli Lilly's specialized AI model dominance
The speakers argued that Eli Lilly is positioned to become a leading AI company by leveraging its proprietary clinical data and dedicated GPU infrastructure to build specialized models rather than relying on generalist LLMs.
The argument
The guest argued that generalist models face monetization challenges, whereas Eli Lilly's 150-year-old dataset of clinical trials, combined with its own data center of 1,000 Blackwell GPUs and partnerships with NVIDIA and Isomorphic Labs, allows it to directly monetize AI. This specialized approach is expected to streamline FDA approvals and drug discovery, generating direct revenues that bypass the high token costs of general model providers.
The thesis, stress-tested
✓ What validates it
- ✓Eli Lilly successfully brings an AI-designed drug to clinical trials
- ✓Measurable reduction in FDA approval timelines for LLY pipeline
▸ Risks discussed
- ▸High capital expenditure on proprietary data centers
- ▸Clinical trial failures despite AI integration
- ▸Regulatory hurdles from the FDA
Hear it yourself
"We started to go down again all while the stock market was going up nine weeks in a row. So the good news is Bitcoin's not correlated to the stock market anymore. The bad news is, it's down 50% off the highs. I wrote a paper last week to yeah. Last week, in substack about taking a stoic approach to everything in life. But it's really important with with markets. And I think for people that are either a frustrated or b, people that are really happy and pounding on x and the bearish thing. This bubble's gonna unwind. Strategy's gonna go bust. This is the way it all ends. None of that's true, in my opinion."
AFFILIATE LINK · ZORTIX MAY EARN A COMMISSION · NEVER A RECOMMENDATION TO TRADE